Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 9
2004 10
2005 10
2006 11
2007 7
2008 10
2009 9
2010 9
2011 13
2012 16
2013 14
2014 17
2015 9
2016 13
2017 15
2018 16
2019 20
2020 16
2021 20
2022 14
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

243 results

Results by year

Filters applied: . Clear all
Page 1
PARP Inhibitors in Ovarian Cancer.
Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A, Valabrega G. Mittica G, et al. Among authors: aglietta m. Recent Pat Anticancer Drug Discov. 2018;13(4):392-410. doi: 10.2174/1574892813666180305165256. Recent Pat Anticancer Drug Discov. 2018. PMID: 29512470 Free article. Review.
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S. Lenz HJ, et al. Among authors: aglietta m. J Clin Oncol. 2022 Jan 10;40(2):161-170. doi: 10.1200/JCO.21.01015. Epub 2021 Oct 12. J Clin Oncol. 2022. PMID: 34637336 Clinical Trial.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Overman MJ, et al. Among authors: aglietta m. J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. J Clin Oncol. 2018. PMID: 29355075 Free article.
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. van der Graaf WT, et al. Among authors: aglietta m. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. Lancet. 2012. PMID: 22595799 Free article. Clinical Trial.
Fluoropyrimidine-induced cardiotoxicity.
Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, Leone F. Depetris I, et al. Among authors: aglietta m. Crit Rev Oncol Hematol. 2018 Apr;124:1-10. doi: 10.1016/j.critrevonc.2018.02.002. Epub 2018 Feb 7. Crit Rev Oncol Hematol. 2018. PMID: 29548480 Review.
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Boccaccino A, Morano F, Brugia M, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Randon G, Murgioni S, Borelli B, Buonadonna A, Giordano M, Fontanini G, Conca V, Formica V, Aglietta M, Bordonaro R, Aprile G, Masi G, Boni L, Cremolini C. Rossini D, et al. Among authors: aglietta m. J Clin Oncol. 2022 Sep 1;40(25):2878-2888. doi: 10.1200/JCO.22.00839. Epub 2022 Jun 6. J Clin Oncol. 2022. PMID: 35666229 Free PMC article. Clinical Trial.
Translocation-related sarcomas.
Mertens F, Antonescu CR, Hohenberger P, Ladanyi M, Modena P, D'Incalci M, Casali PG, Aglietta M, Alvegård T. Mertens F, et al. Among authors: aglietta m. Semin Oncol. 2009 Aug;36(4):312-23. doi: 10.1053/j.seminoncol.2009.06.004. Semin Oncol. 2009. PMID: 19664492 Review.
Evolution of the Experimental Models of Cholangiocarcinoma.
Massa A, Varamo C, Vita F, Tavolari S, Peraldo-Neia C, Brandi G, Rizzo A, Cavalloni G, Aglietta M. Massa A, et al. Among authors: aglietta m. Cancers (Basel). 2020 Aug 17;12(8):2308. doi: 10.3390/cancers12082308. Cancers (Basel). 2020. PMID: 32824407 Free PMC article. Review.
Next generation immune-checkpoints for cancer therapy.
Donini C, D'Ambrosio L, Grignani G, Aglietta M, Sangiolo D. Donini C, et al. Among authors: aglietta m. J Thorac Dis. 2018 May;10(Suppl 13):S1581-S1601. doi: 10.21037/jtd.2018.02.79. J Thorac Dis. 2018. PMID: 29951308 Free PMC article. Review.
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.
Rotolo R, Leuci V, Donini C, Galvagno F, Massa A, De Santis MC, Peirone S, Medico G, Sanlorenzo M, Vujic I, Gammaitoni L, Basiricò M, Righi L, Riganti C, Salaroglio IC, Napoli F, Tabbò F, Mariniello A, Vigna E, Modica C, D'Ambrosio L, Grignani G, Taulli R, Hirsch E, Cereda M, Aglietta M, Scagliotti GV, Novello S, Bironzo P, Sangiolo D. Rotolo R, et al. Among authors: aglietta m. Clin Cancer Res. 2023 Feb 1;29(3):621-634. doi: 10.1158/1078-0432.CCR-22-0761. Clin Cancer Res. 2023. PMID: 36165915 Free PMC article.
243 results